MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today

Locations
Careers
Contact Us
Our Doctors
- Español
- عربى
- 中文
- Türkçe

Clear

close

Search MD Anderson

MyChart

Donate Today

Locations
Careers
Contact Us
- Español
- عربى
- 中文
- Türkçe

Request an Appointment
New Patients
Current Patients
Referring Physicians

Patients & Family
Prevention & Screening
Donors & Volunteers
For Physicians
Research
Education & Training
Cancer Moonshots

Diagnosis & Treatment

Clinical Trials

Clinical Trials Detail

Top

Study #2016-0785

A Phase II Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients with High-Risk CLL

MD Anderson Study Status

Enrolling

Treatment Agent

Ibrutinib, Venetoclax

Description

This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.